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Tuberculosis (TB) disease activation is now believed to arise due to a lack of inflammatory homeostatic control at either end of
the spectrum of inflammation: either due to immunosuppression (decreased antimicrobial activity) or due to immune activation
(excess/aberrant inflammation). Vitamin D metabolites can increase antimicrobial activity in innate immune cells, which, in
the context of HIV-1 coinfection, have insufficient T cell-mediated help to combat Mycobacterium tuberculosis (MTB) infection.
Moreover, maintaining vitaminD sufficiency prior toMTB infection enhances the innate antimicrobial response to T cell-mediated
interferon-𝛾. Conversely, vitamin D can act to inhibit expression and secretion of a broad range of inflammatory mediators and
matrix degrading enzymes driving immunopathology during activeTB and antiretroviral- (ARV-)mediated immune reconstitution
inflammatory syndrome (IRIS). Adjunct vitamin D therapy during treatment of active TB may therefore reduce lung pathology
and TB morbidity, accelerate resolution of cavitation and thereby decrease the chance of transmission, improve lung function
following therapy, prevent relapse, and prevent IRIS in those initiating ARVs. Future clinical trials of vitamin D for TB prevention
and treatmentmust be designed to detect themost appropriate primary endpoint, which in some cases should be anti-inflammatory
and not antimicrobial.
1. Introduction
In recent years vitamin D has become a buzzword in dis-
ease prevention and treatment. There is an ever-expanding
list of communicable and noncommunicable diseases being
associated with vitamin D deficiency, including types 1
and 2 diabetes mellitus, rheumatoid arthritis, cardiovascular
disease, osteoporosis, multiple sclerosis, depression, irritable
bowel disease, asthma, colorectal, lung and breast cancers,
upper respiratory tract infections, tuberculosis (TB), and
HIV/AIDS progression and mortality [1–6]. No longer is
vitamin D considered solely a regulator of calcium and bone
homoeostasis; it is now recognized to have a diverse range
of physiological functions, including cellular differentiation,
proliferation, activation, and death [7]. One reason for its
pleiotropic actions is the fact that vitamin D differs from
most other vitamins in that its primary active metabolite,
1𝛼,25-dihydroxyvitamin D (1,25[OH]
2
D), is a steroid hor-
mone. Moreover, unlike many other vitamins which act as
antioxidants or enzyme cofactors, vitamin D metabolites
are ligands for the vitamin D receptor (VDR) and binding
activates receptor-mediated signalling. Binding to the cell
membrane receptor (mVDR) elicits rapid responses through
activating intracellular signalling pathways, while binding
to the nuclear receptor (nVDR) forms an activated ligand-
dependent transcription factor complex that regulates the
expression of more than 900 genes and microRNA [8–10].
Our research groups have been working on aspects of
the genetic, molecular, and cell-mediated effects of vitamin
D metabolites on Mycobacterium tuberculosis (MTB) infec-
tion in vitro, ex vivo, and in vivo, for the past 15 years.
More recently, we have extended our research to investigate
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the interaction between vitamin D and TB in the context
of HIV-1 coinfection and TB/HIV immune reconstitution
inflammatory syndrome (IRIS). Here we review the impact
of our findings in the context of the field and propose how
we envisage vitamin D therapy that might have the greatest
impact on reducing TB and HIV-1-associated incidence and
morbidity.
2. Causes of Vitamin D Deficiency
2.1.Mechanisms of VitaminDAcquisition. Humans primarily
obtain vitamin D through skin exposure to ultraviolet B
(UVB) irradiation, cleaving 7-dehydrocholesterol, stored in
the epidermis, and following isomerization forming vitamin
D
3
. Alternate dietary sources of vitamin D
3
(animal-derived)
and vitaminD
2
(plant- and fungus-derived) are also available,
including oily fish, mushrooms, and supplemented dairy
products; however their contribution to maintaining vitamin
D sufficiency is much lower, except in the case of heavy
supplementation or intake. The classic model of vitamin
D metabolism involves its initial conversion in the liver
to 25-hydroxyvitamin D (25[OH]D), the serum measure
of vitamin D status, followed by 1𝛼-hydroxylation in the
kidney by the cytochrome P450 enzyme CYP27B1 to form
1,25[OH]
2
D, the activemetabolite (Figure 1). 1,25[OH]
2
Dacts
on the kidney, the gastrointestinal tract, and the bones to
regulate serum calcium concentration. It regulates its own
catabolism via induction of the 24-hydroxylase CYP24A1
and its own metabolism through negative regulation of
parathyroid hormone (PTH), which induces CYP27B1 in
response to hypocalcaemia.
The increasing number of studies investigating diverse
physiological functions of vitamin D has resulted in some
contention in the field as how to define vitamin D defi-
ciency; this is because the minimum activating concen-
tration of vitamin D metabolites varies depending on the
cellular process investigated [11]. Consensus has not been
met, but the most frequently used definition of vitamin D
deficiency (25[OH]D < 20 ng/mL or 50 nM) remains defined
by the required serum concentration to maintain calcium
homeostasis and to prevent secondary hyperparathyroidism
[12].
2.2. Mechanisms of Vitamin D Deficiency. Decreased 25-
[OH]D levels can be caused by a variety of factors but
primarily decreased exposure to UVB, which is particularly
observed in geographical regions further from the equator,
where UVB radiation is decreased due to the angle of the sun,
which is exacerbated in winter or through behavioural avoid-
ance patterns such as decreased time outdoors, increased sun-
screen use, and full body covering for cultural reasons [13–15].
Non-UVB related causes include increased body mass index
(BMI) due to sequestration of 25[OH]D in adipose tissue,
decreased absorption of vitaminD in the intestines, increased
1𝛼-hydroxylation of 25[OH]D, or increased catabolism of
25[OH]D and 1,25[OH]
2
D by CYP24A1 [16, 17]. These per-
turbations of vitamin D metabolism are influenced by genet-
ics factors, including polymorphisms identified in CYP450
enzymes (Figure 1) [18] as well as disease states and medica-
tion [19–25].
2.2.1. Infection Induced Vitamin D Deficiency. While vitamin
D deficiency is associated with TB incidence and HIV-
1 disease progression, vitamin D metabolism can also be
modulated by MTB and HIV-1 infection. Toll-like receptor
(TLR)1/2 stimulation byMTB antigens andHIV-1 gp120 pep-
tides induces CYP27B1 expression in infected macrophages
in vitro. This accelerates 1,25[OH]
2
D production and subse-
quent CYP24A1 expression. [26, 27]. Exacerbated by the fact
that 1,25[OH]
2
D has a 4–8 hr half-life compared to the 15–18
days half-life of 25[OH]D [28, 29], in vivo, these infections
may therefore result in exhaustion of available 25[OH]D if
sufficient intake is not maintained.
2.2.2.Drug InducedVitaminDDeficiency. Drugs used to treat
TB and HIV-1 also interfere with CYP450 enzyme levels.
The first-line TB drugs rifampicin and isoniazid have been
shown to decrease 25[OH]D in TB patients one month after
therapy initiation and that this decrease is maintained after 6
months [19, 20, 30]. Protease inhibitors (PI) are also potent
inhibitors of hepatic CYP450 enzymes [21]. Treatment of
resting macrophages with HIV-1 antiretroviral PIs nelfinavir
(NFV), indinavir (IDV), and ritonavir (RTV) also inhibits 25-
hydroxyation and 1𝛼-hydroxylation of vitaminDmetabolites,
consequently reducing bioactive 1,25(OH)
2
D [22]. While
RTV has the greatest inhibition of CYP27B1, all PIs similarly
inhibit CYP24A1 activity [22]. Conversely, while not having
a direct effect on CYP450 enzymes, tenofovir (TFV), a
nucleoside reverse transcriptase inhibitor (NRTI), is thought
to mediate an indirect effect on vitamin D metabolism,
through induced proximal renal tubular dysfunction, poten-
tially affectingCYP27B1 activity and 1,25[OH]
2
Dproduction.
We have also shown that the TFV-associated increase in PTH
levels is modified by sex and ethnicity [25]. Efavirenz (EFV)
on the other hand, a nonnucleoside reverse transcriptase
inhibitor (NNTRI), decreases serum 25[OH]D levels though
inducing CYP24A1 expression which effectively limits an
increase in 25[OH]D following vitamin D supplementation
[23, 24]. Together, these results suggest that TB and HIV-
1 patients on chronic treatment are at risk of drug-induced
vitamin D deficiency which may exacerbate preexisting
infection-associated deficiency.
3. Vitamin D Deficiency, Genetic Variation,
and TB/HIV Disease
We first described the prevalence of vitamin D deficiency
in TB patients in London, UK, in 2000 and demonstrated
that individuals from certain populations who carry a VDR
polymorphism at the Taq1 locus (rs731236), and are vitamin
D deficient, have increased susceptibility to TB [31]. Further
to this we identified a similar association with vitamin D
deficiency and TB incidence in individuals carrying the
vitamin D binding protein (DBP, the serum 25[OH]D trans-
porter) Gc2 haplotype (T420K amino acid change) [32].
We subsequently demonstrated that, in TB patients from
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Figure 1: Vitamin D metabolism pathway. Proteins with genetic polymorphisms associated with vitamin D deficiency are highlighted (red).
various ethnic backgrounds, DBP haplotypes are significantly
associated with variation in serum DBP levels; patients of
African ancestry who more commonly carry the DBP Gc1F
haplotype have low circulating DBP levels, while Eurasians
who commonly carry the Gc1S haplotype (D416E amino acid
change) have high circulatingDBP levels and individuals who
areGc2 orGc1F-Gc1S have intermediateDBP levels (Figure 2)
[33]. This observation is significant in light of the “free
hormone hypothesis” which states that only DBP-unbound
“free” 25[OH]D is bioactive; consequently serum DBP levels
impact the level of bioactive 25[OH]D. In support of this
hypothesis, recent studies have found that “free” 25[OH]D
is more associated than total 25[OH]D to PTH concentra-
tion and bone density [34, 35]. Furthermore, different DBP
haplotypes have different 25[OH]D binding affinities [36].
We assisted collaborators in demonstrating that monocytes
treated with 25[OH]D and cultured in the presence of low-
affinity Gc2 or Gc2-Gc1S DBP have a greater induction of
vitamin D-associated gene transcription than those cultured
with high affinity Gc1F DBP [37].
VitaminD deficiency has now been shown to be common
in patients with active TB [31, 38] and is more prevalent in
persons with latent TBwho progress to active disease [39]. As
mentioned, variation in UVB levels according to season and
latitude impacts vitaminD levels [40]. Concordantly, we have
shown that despite the general sunny climate of Cape Town,
South Africa, at latitude 33∘S, 75% of TB patients are vitamin
D deficient, increasing to 86% in HIV-1 coinfected patients
(Figure 3(a)) [38].This is in contrast to Uganda, an equatorial
country, where only 44% of hospitalized TB patients were
found to be vitamin deficient, but again 83%ofHIV-1 infected
TB patients (with CD4 < 200 cells/mm3) were vitamin D
deficient [41]. We also found that TB incidence in Cape
Town oscillates seasonally, with the lowest rates occurring in
autumn/winter, following peak 25[OH]D levels in summer
(Figures 3(b) and 3(c)) [38]. Seasonality in TB notification
has also been identified in Australia, USA, UK, and China
with the strongest association in regions with larger seasonal
fluctuation in UV index [42–45].
Apart from increased TB risk, vitamin D deficiency
has also been identified to associate with increased risk
of mortality and AIDS events in those with HIV-1, from
a broad range of populations [46–48]. This association is
further strengthened by the determination that two poly-
morphisms in the VDR (rs1544410 and rs2228570) associate
with increased susceptibility to HIV-1 infection and rapid
HIV-1 disease progression in adults and children [49–51].
An additional polymorphism in the 7-dehydrocholesterol
4 Scientifica
600
400
200
0
2-way AVOVA
Source of variation
Interaction
Ethnicity
Genotype
P value
0.2166
0.9043
<0.0001
D
BP
 (𝜇
g/
m
L)
Gc1F Gc1F/Gc2 Gc2 Gc1F/Gc1S Gc2/Gc1S Gc1S
A
FR
EU
A
A
FR
EU
A
A
FR
EU
A
A
FR
EU
A
A
FR
EU
A
A
FR
EU
A
Figure 2: Serum vitamin D binding protein (DBP) concentration in
patients with newly diagnosed pulmonary TB stratified by DBP Gc
haplotype and ethnic group. Patients of Gc1F/1F haplotype had the
lowest DBP concentrations and those with Gc1S/1S haplotype had
the highest concentrations. Haplotypes frequency varied between
ethnic groups of African ancestry (AFR) and Eurasian ancestry
(EUA). The figure is adapted from Coussens et al. [33].
reductase (DHCR7, rs12785878) also associates with rapid
disease progression in children > 2 years [51].
4. The Inflammatory Balance in
TB/HIV Progression
Upon initial infection with MTB, alveolar macrophages and
dendritic cells (DC) recruit neutrophils, monocytes, T cells,
and NK cells to activate cell-mediated killing. Upon recruit-
ment, these cells encase the infected phagocytes, forming a
granuloma that walls off the infected cells preventing MTB
escape into surrounding tissue. A balanced inflammatory
response from all these cells within these granulomas is
vital to control excessive MTB replication and limit excessive
inflammation,which is responsible for the immunopathology
associated with TB morbidity. Loss of this finely balanced
immune pressure, through various mechanisms of immuno-
suppression or immune activation, can therefore result in
latent tuberculosis progressing to active disease [52, 53].
TB resurgence in sub-Saharan Africa is linked to the
HIV-1 pandemic [54]. Coinfection with HIV-1 is thought to
increase susceptibility to TB via a number of mechanisms,
primarily through dysfunctional and decreased numbers of
CD4+ T cells and impaired T cell activation by phagocytes
[55–58]. Coinfection of peripheral blood mononuclear cells
(PBMC) and macrophages with HIV-1 and MTB has been
shown to mutually increase replication of both pathogens
in vitro [59, 60]. MTB infection induces HIV-1 replication
via a number of mechanisms, including upregulating host
transcription factors nuclear factor-kappa B (NF-𝜅B) and
nuclear factor of activated T cells-5 (NFAT5) which drive
HIV-1 LTR transcription [60, 61]. Conversely, the effect of
HIV-1 on the macrophage response is variable and subtle,
modifying cytokine and chemokine production required for
T cell recruitment and activation [59, 62].
Vitamin D metabolites have been shown to both induce
cell-mediated antimicrobial activity against MTB and HIV-
1 and have anti-inflammatory effects, regulating cytokine,
chemokine, growth factor, and matrix metalloproteinase
(MMP) expression [7]; consequently, the exact mechanism
by which vitamin D may help to prevent and treat TB and
HIV-1 remains unclear. More likely, its dual roles will have
varying degrees of impact depending on the stage of infection
and treatment.
5. Antimicrobial Effects of Vitamin D
in relation to MTB and HIV-1 Infection
5.1. Alternate Vitamin D Receptor Activation. The first mech-
anisms identified by which 1,25[OH]
2
D
3
mediated innate
cellular control of MTB infection involved induction of
nitric oxide, NAPDH-dependent oxidases, and phagolyso-
some fusion [63–65]. Vitamin D was shown to mediate its
effect on the latter two functions via phosphoinositide 3-
kinase (PI3K) signaling, suggesting that the antimicrobial
effects of vitamin D were mediated by the mVDR [63, 64].
However, through the utilisation of specificmVDRandnVDR
inhibitors we determined that the predominant mechanism
of vitamin D anti-MTB activity was actually mediated via
the nVDR and that this was associated with 1,25[OH]
2
D
3
induction of cathelicidin antimicrobial peptide (CAMP)
gene expression [66], the product of which is enzymatically
cleaved to produce the active antimicrobial agent, cathelicidin
(LL-37) [67].
5.2. Cathelicidin-Mediated Antimicrobial Activity. Vitamin D
regulation of CAMP expression byMTB-infected monocytes
was first demonstrated a year earlier, by Liu et al. [27]
who also showed that LL-37 directly inhibits MTB viability
in liquid culture. This gene regulation by vitamin D was
explained by CAMP having three vitamin D response ele-
ments (VDRE) in its promoter [68]. In the same paper Liu
et al. demonstrated that TLR1/2 stimulation of MTB-infected
monocytes upregulates expression of VDR and CYP27B1 and
that monocytes grown in the presence of 25[OH]D-replete
serum upregulated CAMP expression.Thus, monocytes have
the capacity to utilise serum 25[OH]D to induce intracellular
antimicrobial gene expression [27].
Since its first identification in monocytic phagocytes,
further studies have since reported that neutrophils, T cells,
B cell, NK cells, DC, mast cells, and epithelial cells in the
upper and lower respiratory tract also express CAMP [69–
71]. This suggests that vitamin D metabolites could induce
antimicrobial activity in a diverse range of cells in response
to MTB and HIV-1 infection.
The bactericidal activity of cathelicidin is mediated by its
ability to bind and disrupt bacterial cell wall phosphatidyl-
glycerol monolayers [72]. However, recent work has shown
that pro-LL-37 (hCAP18) also induces autophagy though
upregulating expression of beclin-1 (BECN1) and autophagy
protein 5 (ATG5), which mediate activation of p38 mitogen
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Figure 3: Active TB associates with vitamin D deficiency and seasonal fluctuations in Cape Town, South Africa. (a) Serum 25[OH]D
concentration by HIV and TB status. Bars represent means. Dashed line represents limit of detection (10 nmol/L). (b) New TB notifications
by quarter, 2003 to 2010. (c) Monthly variation in mean serum 25[OH]D concentration (all participants, 𝑛 = 370). Error bars indicate SD.
The figure is adapted fromMartineau et al. [38].
activated protein kinase (MAPK) and extracellular signal-
regulated kinase (ERK) 1/2 signaling [73]. Autophagy has
recently been identified as a key intracellular process to
antagonize MTB-mediated inhibition of phagosome mat-
uration, a key mechanism by which MTB subverts the
innate immune response [74]. Autophagy also increases the
production of bacterial degradation products in antigen
presenting cells for pattern recognition receptor activation
and presentation to the adaptive immune system [75]. More-
over, 1,25[OH]
2
D
3
-induced autophagy in monocyte-derived
macrophages (MDM) has also been shown to restrict HIV-
1 replication [76]. We have obtained similar results on HIV-
1 replication using MDM differentiated in the presence
of physiological concentrations of 25[OH]D
3
, although we
hypothesize an alternate mechanism of action mediated by
25[OH]D
3
regulating secretion of CCL chemokines which
regulate HIV-1 replication (manuscript in prep.).
In general, all papers that report an effect of CAMP
induction on colony forming unit (CFU) restriction demon-
strate only a small effect, in the range of 2-fold [27, 66,
77, 78]. Moreover, almost all studies present the induction
of CAMP expression with the insinuation that LL-37 is
produced, thus mediating the restriction of growth. However
proteinase 3 (PR3) which is required for LL-37 cleavage from
the propeptide is predominantly expressed in neutrophils
[67].Therefore in single cell culture systems involvingmono-
cytic phagocytes, the likelihood of LL-37 production is low.
Moreover, the only way of detecting LL-37 production is
via Western blot which is rarely incorporated as a proof
of concept and thus while authors interpret their results to
reflect LL-37 production, in fact they may only be observing
the effects of hCAP18.
5.3. Interferon-𝛾 Regulation of the Vitamin D Response. The
antimicrobial effects of vitamin D metabolites have also
been shown to be increased by cotreatment with interferon-
gamma (IFN-𝛾) as it can enhance macrophage levels of
1,25(OH)
2
D
3
by antagonizing the ability of 1,25(OH)
2
D
3
to
induce CYP24A1 and suppress CYP27B1 [79, 80]. Work by
Fabri et al. [78] showed that stimulating human monocytes
with IFN-𝛾 for 24 hours in 10% vitamin D-sufficient human
serum increases the 1,25(OH)
2
D/24,25[OH]
2
D ratio, induces
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Figure 4: Interferon-gamma (IFN-𝛾) enhances the antimicrobial action of monocyte-derived macrophages (MDM) infected with
Mycobacterium tuberculosis only in vitaminD sufficient conditions. (a)MDMdifferentiated in the presence of vitaminD significantly inhibits
MTB growth in response to postinfection IFN-𝛾 (200 IU/mL) treatment.This scenario represents the logical physiological process of infection
response under vitamin D sufficient conditions. (b) However, pretreatment of MDM with IFN-𝛾 (200 IU/mL) for 48 hr before infection and
during infection in vitaminDdeficient conditions does not enhance the response to vitaminD treatment after infection.Mean± SD, 𝑛 = three
donors, each in triplicate.
CAMP expression, and increases autophagolysosomal fusion
but not when using vitamin D-deficient human serum. This
is surprising given the fact that the final concentration of
25[OH]D in culturewas only 10%of the serumconcentration.
However, we have similar results demonstrating that, in
macrophages grown in the presence of 100 nM 25[OH]D
3
during differentiation and throughout MTB infection (repli-
cating physiological vitamin D sufficiency), IFN-𝛾 treat-
ment after infection enhances the response to vitamin D
(Figure 4(a)). Conversely, IFN-𝛾 treatment ofMDM for 48 hr
preinfection and during infection (in vitamin D deficient
conditions) had no effect on vitamin D-mediated MTB
growth restriction when 100 nM 25[OH]D
3
was added after
infection (Figure 4(b)). Together with the observations by
Fabri et al. [78], these results suggest thatmaintaining vitamin
D sufficiency prior to infection will enhance T cell-mediated
innate cell responses during MTB infection.
5.4. Neutrophil-Derived Antimicrobial Peptides. In addition
to CAMP induction, 1,25[OH]
2
D has also been shown to
increase expression of another antimicrobial peptide beta-
defensin 2 (DEFB4) [78, 81, 82]. In comparison to CAMP,
the DEFB4 promoter only has one VDRE but two NF-𝜅B
binding sites. Consequently, its expression is regulated by
dual signalingmechanisms, with vitaminD a smaller compo-
nent [81]. Moreover, while the effect of vitamin Dmetabolites
on antimicrobial peptide expression is commonly studied in
monocytes or macrophages in vitro, in vivo these peptides
are more abundant in neutrophils and epithelial cells [83,
84]. We have demonstrated that, in whole blood (WB)
assays, the greatest control on MTB growth is mediated
by neutrophils and that the antimicrobial peptides human
neutrophil peptide 1–3 (HNP-13) and neutrophil gelatinase-
associated lipocalin (NGAL) (the latter in the presence of
iron) elicit more efficient killing of MTB than LL-37 [85].
Therefore, to truly understand the in vivo related effects
of vitamin D antimicrobial action, studies should focus on
integrating in vivo studies and ex vivo analysis of mixed-
cell cultures to better understand the antimicrobial actions of
vitamin D.
5.5. Ex Vivo and In Vivo Antimicrobial Effects of Vitamin D.
To investigate physiologically significant effects of vitamin
D on MTB restriction in humans, we initially conducted a
proof of concept trial, investigating the effect of a single bolus
dose of vitaminD
2
(100,000 IU), given to healthyTB contacts,
on restriction ofMycobacteriumbovisBCG-lux luminescence
(which correlates with CFU [66]), in an ex vivoWB culture, 6
weeks after administration [86]. This assay ensured the pres-
ence of neutrophil-derived products, particularly PR3 for LL-
37 production.This dose of vitaminD
2
significantly increased
participants 25[OH]D levels 6weeks after administration and
resulted in a significant restriction in BCG-lux luminescence
24 hr and 96 hr after infection of WB compared to blood
taken before supplementation [86].
Based on these results we conducted a trial of high-dose
adjunctive vitamin D
3
(100,000 IU, fortnightly for 8 weeks)
during intensive phase treatment of pulmonary TB patients,
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from diverse ethnic backgrounds, in London, UK [87].There
was a trend to reduction in median time to sputum culture
conversion with vitamin D
3
(36.0 days) compared to placebo
(43.5 days, 𝑃 = 0.14). In subset analysis, we identified a sig-
nificant interaction between response to vitamin D
3
and the
VDRTaqI polymorphism, such that those homozygous reces-
sive had a significant reduction in time to culture conversion
with vitamin D
3
supplementation. Furthermore, refining
our analysis to the per-protocol subset, who amongst other
criteria received >3 doses of vitamin D
3
and was not HIV-
1 infected or taking corticosteroids, vitamin D
3
significantly
reduced time to sputum smear conversion [88]. One reason
for the significant response in the per-protocol cohort is likely
greater and more frequent supplementation. We found that
fortnightly doses of 100,000 IU (approx. 7,000 IU/day) only
increased mean 25[OH]D, in the entire cohort, above the
optimal threshold of 75 nM after 4 weeks. We hypothesize
that a greater antimicrobial effect of vitamin D
3
may be
achieved with a higher, more frequent dose or through
supplementation with 25[OH]D
3
rather than vitamin D
3
to
rapidly raise serum 25[OH]D. Further trials are required to
comprehensively conclude whether these alternative regimes
will improve the efficacy of adjunct vitamin D
3
to reduce
time to culture conversion. However, despite the inconclusive
effect of vitamin D
3
on MTB clearance in our trial, we
did find a significantly greater and widespread reduction in
inflammatory markers in those receiving vitamin D
3
during
anti-TB therapy, compared to placebo, irrespective of VDR
polymorphism [88]. This suggests that vitamin D’s greatest
role may be resolution of pathologic inflammation during TB
treatment.
6. The Anti-Inflammatory Action of
Vitamin D in relation to TB
The immunomodulatory effects of vitamin D have been
extensively studied, even before the identification of the
cell-mediated antimicrobial mechanism of vitamin D. The
molecular link between vitamin D and the immune system
was first identified in the early 1980s with the discovery
that monocytes and macrophages express VDR, they can
synthesize 1,25(OH)
2
D
3
and that 1,25(OH)
2
D
3
induces dif-
ferentiation of monocytes into macrophage-like cells which
have increased phagocytic, lysozyme, and migration activity
[89–91].
6.1. Anti-Inflammatory Effects of Vitamin D. With regard to
the anti-inflammatory roles of vitamin D during MTB infec-
tion, we first demonstrated that 1,25[OH]
2
D
3
inhibits IFN-
𝛾, TNF, and IL-12p40 expression and secretion from MTB-
infected PBMC, while concomitantly inducing NOS2A and
CAMP expression [66]. During treatment of pulmonary TB,
we have demonstrated that vitamin D
3
significantly inhibited
secretion of proinflammatory cytokines IL-1RA, IL-6, IL-
12p40, and TNF from WB stimulated with MTB peptides,
ESAT-6 and CFP-10, while attenuating the reduction in IL-4,
CCL5, and IFN-𝛼 observed during intensive-phase therapy
[88]. Moreover, we found that vitamin D
3
supplementation
increased the lymphocyte :monocyte ratio, previously shown
to be a marker of healing lesions [92], and accelerated the TB
therapy-induced reduction in acute phase markers, erythro-
cyte sedimentation rate (ESR) and C-reactive protein (CRP),
and IFN-𝛾 and IFN-𝛾-simulated chemokines CXCL9 and
CXCL10. While this may be useful during treatment, based
on these observations, maintaining vitamin D sufficiency
prior to infection could cause a decrease in proinflammatory
responses during initial infection which is counterintuitive to
a protective response. However, in those with latent TB or
acute infection, vitamin D may modulate the inflammatory
response to limit excessive inflammation associated with
disease activation, while simultaneously enhancing antimy-
cobacterial activity.
The exact mechanisms of vitamin D’s anti-inflammatory
effects are not yet fully delineated. It cannot be ruled out
that the anti-inflammatory effects we observed in our vitamin
D
3
trial are due to enhanced bacillary killing. However, in
vitro evidence suggests that vitamin D metabolites will have
a direct effect of inflammatory responses in vivo as it has
been shown that they directly inhibit MAPK and NF-𝜅B
signaling. The expression of MAPK phosphatase-1 (MKP-1,
which dephosphorylates activated MAPK) is upregulated in
human monocytes by 1,25[OH]
2
D
3
and this associates with
increased binding of the nVDR and increased histone H4
acetylation at the VDRE in the MKP-1 promoter [93]. NF-𝜅B
activity is similarly inhibited by 1,25[OH]
2
D
3
which increases
I𝜅B𝛼 levels and decreases its phosphorylation (the first step
in degradation of the NF-𝜅B inhibitor) leading to decreased
NF-𝜅B nuclear translocation and activity [94, 95].
We have also shown that 1,25[OH]
2
D
3
induces IL-10 from
PBMC in vitro, and vitamin D supplementation increases IL-
4 secretion in WB MTB antigen stimulation assays, suggest-
ing that vitamin D polarizes towards a Th2 response. Others
have also shown that vitaminDmetabolites induce regulatory
T cell (Treg) differentiation and FoxP3 expression where
seasonal vitamin D deficiency is associated with decreased
Foxp3 expression by Tregs and that serum 25[OH]D levels
correlate with Treg function [96, 97]. While it is unclear
whether vitamin D regulates Treg function in TB, we have
recent data showing that 25[OH]D
3
induces expression of the
natural innate inhibitor IL-37 in MTB-infected macrophages
(manuscript in prep.). IL-37, a member of the IL-1 family (aka
IL-1F7), has recently been identified to suppress macrophage
TLR-induced cytokine and chemokine secretion, by between
92–98% for IL-1𝛼, TNF, and IL-6 as well as IL-1𝛽, IL-12, G-
CSF, and GM-CSF to a lesser extent, without regulating IL-10
or IL-1RA. IL-37 primarilymediates its effect by translocating
to the nucleus and forming a complex with Smad3 as well
as reducing phosphorylation of p38 MAPK and STAT1–4.
Moreover, secreted IL-37 is able to bind to the IL-18Ra chain,
preventing IL-18Ra from recruiting the IL-18Rb chain and
also bind to IL-18BP, antagonizing IL-18 mediated-responses
[98, 99]. IL-37may therefore be the fundamental mediator by
which vitamin D elicits its broad anti-inflammatory effects.
6.2. Anti-MMP Effect of Vitamin D. Further to an effect of
vitamin D on inflammatory cytokine secretion, we have also
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demonstrated that 1,25[OH]
2
D
3
inhibits expression, secre-
tion, and/or activity of MMP which are linked to cavitation
and granuloma formation inTBdue to their ability to degrade
all components of the extracellular matrix (ECM) [100–
103]. In MTB-infected monocytes and PBMC 1,25[OH]
2
D
3
treatment inhibits MMP-1, MMP-7, and MMP-10, while it
constitutively inhibitsMMP-9, irrespective of infection [104].
Under the same conditions, we observed increased IL-10 and
prostaglandin E2 (PGE2) secretion, both known to negatively
regulate MMP secretion/activity [105, 106]. The effect of
1,25[OH]
2
D
3
on MMP-7 and MMP-9 has also been seen
using PBMC from TB patients [107] and we have found
that adjunctive vitaminD
3
during anti-TB therapy suppresses
plasma MMP-9 levels [88]. Vascular remodeling is also a
crucial component of lung destruction in active TB [108].
Human vascular endothelial cells also metabolize 25[OH]D
3
,
while treatment with 1,25[OH]
2
D
3
decreases endothelial cell
proliferation and increases cellular adhesion to endothelial
cells [109]. Therefore, adjunctive vitamin D may also help to
resolve and prevent lung tissue destruction during infection
as well as resolve pathology and restore lung function during
TB treatment.
While the majority of work on MMP focuses on tissue
destruction, MMP also plays a role in regulating inflamma-
tion. As endopeptidases they have been shown to release TNF
and IL-6 from cell surfaces and inactivate IL-1𝛽. The release
and degradation of TNF and IL-1 isoforms are potential
feedback regulatory loops as both cytokines are implicated
in MMP induction [110–112]. Moreover, MMP regulates cell
recruitment, by processing of chemokines and through cleav-
ing fragments of ECM which act as chemotactic signals for
inflammatory cells, including elastin degradation products in
lung parenchyma [113–117].
7. The Interaction between Vitamin D,
HIV-1, and TB
7.1. Vitamin D Regulation of HIV-1 Transcription. The regu-
lation of cytokines and chemokines by vitamin D not only
impacts TB inflammation, but also has the potential to impact
HIV-1 replication. While we have discussed the potential
autophagy-mediated antimicrobial action of vitamin D on
HIV-1 replication, the inhibition of TNF, IL-6, and CCL2
secretion by vitamin D and its metabolites in vivo and in
vitro [66, 88, 93, 118] has the potential to reduce HIV-
1 replication, through inhibiting NF-𝜅B-mediated HIV-1
transcription [60]. We are currently investigating whether
vitaminD supplementation inhibits ex vivoHIV-1 replication
in PBMC, via these mechanisms. Recently, 1,25(OH)
2
D
3
was also found to regulate microRNA expression, including
inducing miRNA-22, which targets NFAT5 [10]. As this
transcription factor has been shown to regulate HIV-1 LTR
transcription in macrophages, miRNA-22 induction may be
an additional mechanism by which vitamin D inhibits HIV-1
replication [61]. While ARV is successful in decreasing HIV
viral load and improving CD4 cell count, these observations
suggest that vitamin D supplementation may have the ability
to target clearance of the tissue viral reservoirs that ARV is
unable to eradicate, potentially further decreasing TB risk in
HIV-1 infected individuals.
In support of this, a recent prospective study of TB
incidence in HIV-1 infected individuals initiating ARV ther-
apy and receiving nonvitamin D containing multivitamins
identified a significant correlation between vitamin D defi-
ciency and incidence of pulmonary TB but not malaria or
pneumonia [119]. Analysis of the same cohort also showed
that vitamin D deficiency was significantly associated with
increased all-cause mortality, compared to vitamin D suffi-
ciency [120].
7.2. Vitamin D and TB/HIV Immune Reconstitution Inflam-
matory Syndrome. A frequent complication of ARV initia-
tion in HIV-1 infected individuals with other opportunistic
infections, including MTB and Cryptococcus, is the devel-
opment of immune reconstitution inflammatory syndrome
(IRIS). Paradoxical TB-IRIS occurs in TB patients who are
clinically improving on anti-TB therapy, who begin ARV
and develop paradoxical deterioration [121].We have demon-
strated that, in cross-sectional analysis, patients who develop
TB-IRIS have a higher frequency of IFN𝛾-secreting T cells
recognizing MTB antigens, compared to similar patients
treated for both HIV-1 and TB who did not develop IRIS.
However, over 8 weeks longitudinal analysis during ARV
initiation, all patients, irrespective of IRIS development, have
dynamic changes in the frequency of antigen-specific IFN𝛾-
secreting T cells, suggesting that these changes are not causal
[122]. We have since identified a myeloid-derived hyper-
inflammatory profile involving proinflammatory cytokines
IFN-𝛾, IL-1𝛽, IL-2, IL-6, IL-8, IL-10, IL-12p40, GM-CSF,
and TNF and increased MMP-1,-3,-7, and -10 [123, 124].
This suggests that IRIS may develop due to overstimulation
by MTB antigens of innate immune cells which could be
inhibited by vitamin D.
In a study of the use of corticosteroid (CTC) therapy to
prevent TB-IRIS, we found that while CTC use decreased
CXCL10, IFN𝛾, IL-6, IL-8, IL-10, IL-12p40, IL-18, and TNF
prior to ART initiation, it did not prevent IRIS onset,
although it did decrease severity, and that severe vitamin
D deficiency (total 25(OH)D < 25 nmol/L) was associated
with higher baseline IL-6, IL-8, and TNF, irrespective of
IRIS status [125]. IRIS development is also associated with
higher MTB antigen load and lower CD4 cell count [121].
Therefore as vitamin D can have a positive impact on
reducing bacterial and viral load, increasing Treg function
and inhibit a broad spectrum of proinflammatory cytokines
andMMP production it may be amore effective therapy than
CTC to prevent IRIS and less subject to adverse events.
8. Future Potential of Vitamin D Therapy in
the Context of TB/HIV
Vitamin D, having dual antimicrobial and anti-inflammatory
properties, has the potential to be utilised for both prevention
and treatment of TB to reduce TB morbidity and, in the
context of HIV-1, decrease TB risk, IRIS incidence/severity,
and HIV/AIDS disease progression. Therefore, what are
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the barriers to translate scientific experience to clinical prac-
tice? Primarily, it is a number of null trials of vitamin D
which have been recently conducted [87, 126–128]. However,
the findings from these unsuccessful trials remain ambiguous
as in many cases an argument could be given that the dose,
regime, or metabolite used was incorrect, that the baseline
context of vitamin D deficiency was not investigated or
reported (we know that vitamin D has the greatest effect
in those most deficient [23]), that the populations were
not geographically at risk of deficiency, or that due to
the interaction of vitamin D with genetic polymorphisms
which are population specific, supplementation may have
differential benefits for various populations, which again are
affected by location and diet.
However, the greatest reason for the lack of significant
effect of vitamin D trials for TB may be that their primary
outcome is a measure of the antimicrobial effect of vita-
min D in combination with highly effective antimicrobial
therapy. We propose that while vitamin D does have anti-
MTB effects, in combination with highly effective anti-TB
therapy, the effect is likely to be modest. By using larger
more frequent bolus doses in larger trials conducted with
sufficient powering, the effect will be detected. However,
it is unlikely to be of sufficient magnitude to justify trials
for treatment shortening in drug-sensitive disease. Rather,
the most significant outcome from our trial of vitamin D
3
during anti-TB therapy was the pleiotropic and expansive
acceleration of resolution of inflammation and an increase
in cellular ratios indicative of healing of lung pathology.
We therefore suggest that future trials of adjunct vitamin D
during TB treatment incorporate a primary endpoint relating
to lung function and lung pathology, in addition to culture
conversion.
Secondly, while the antimicrobial actions of vitamin D
do not outweigh those of intensive-phase therapy, vitamin
D does have the potential to act as preventative therapy in
both TB contacts, who are not immunosuppressed but live in
high burden settings, or in HIV-1 infected individuals with
CD4 counts above the threshold for ARV initiation, and in
those who are drug-resistant TB contacts for which isoniazid
preventive therapy (IPT) is not efficacious.
Finally, the anti-inflammatory, combinedwith antimicro-
bial, effects of vitamin D may have dual roles in preventing
and minimizing the severity of TB-IRIS. Giving vitamin D
prior to ARV initiation may help to both further reduce the
bacterial burden, as antigen load is the greatest known risk
factor for IRIS development, and decrease the inflammatory
environment. This could potentially limit both innate and
adaptive immune cell activation during immune reconstitu-
tion which is the cause of morbidity.
Vitamin D is a potential cheap and widely available
therapy which potentially has wide-ranging benefits for
human health. We are only hindered in our ability to
translate these benefits to the clinic by insufficient clinical
trials evidence of efficacy. However, we will continue to trial
vitamin D in diverse circumstances in the hope of potentially
seeing successful outcomes, which will finally lead to clinical
implementation.
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